Impaired Spinal Cord Glutamate Transport Capacity and Reduced Sensitivity to Riluzole in a Transgenic Superoxide Dismutase Mutant Rat Model of Amyotrophic Lateral Sclerosis

John Dunlop,1 H. Beal McIlvain,1 Yijin She,2 and David S. Howland2
1Neuroscience and 2Molecular Genetics, Wyeth Research, Princeton, New Jersey 08543-8000

We characterized synaptosomal glutamate transport activity in a recently developed transgenic rat model of amyotrophic lateral sclerosis (ALS) overexpressing the G93A Cu2+/Zn2+ superoxide dismutase (SOD1) mutation. Using spinal cord synaptosomes, a significant reduction (43%) in the maximal velocity for high-affinity, Na+–dependent glutamate uptake was observed at disease end stage in G93A rats compared with age-matched controls. Similarly, a 27% reduction in maximum velocity (Vmax) was measured at disease onset, but no difference in spinal cord Vmax values were observed with presymptomatic animals compared with controls. In comparison, we observed no differences in the Vmax for glutamate clearance at disease end stage with synaptosomes from cortex, hippocampus, striatum, cerebellum, and brainstem, indicating a specific deficit in the spinal cord. The pharmacological sensitivity of spinal cord uptake to dihydrokainate suggests that the GLT-1 (glutamate transporter-1) subtype primarily mediates the transport activity. Expression analysis revealed a loss of GLT-1 as well as qualitative changes in GLAST (glutamate/aspartate transporter) but no measurable changes in EAAC1 (excitatory amino acid carrier 1) in spinal cord of end-stage G93A rats, indicating that deficits in glutamate transporters in this rat model may be glial specific. Riluzole, a neuroprotective agent used clinically to slow the progression of ALS, produced an enhancement of spinal cord amino acid carrier 1) in spinal cord of end-stage G93A rats, indicating that deficits in glutamate transporters in this rat model may be glial specific. Riluzole, a neuroprotective agent used clinically to slow the progression of ALS, produced an enhancement of spinal cord amino acid carrier 1) in spinal cord of end-stage G93A rats, indicating that deficits in glutamate transporters in this rat model may be glial specific. Riluzole, a neuroprotective agent used clinically to slow the progression of ALS, produced an enhancement of spinal cord amino acid carrier 1) in spinal cord of end-stage G93A rats, indicating that deficits in glutamate transporters in this rat model may be glial specific. Riluzole, a neuroprotective agent used clinically to slow the progression of ALS, produced an enhancement of spinal cord amino acid carrier 1) in spinal cord of end-stage G93A rats, indicating that deficits in glutamate transporters in this rat model may be glial specific. Riluzole, a neuroprotective agent used clinically to slow the progression of ALS, produced an enhancement of spinal cord amino acid carrier 1) in spinal cord of end-stage G93A rats, indicating that deficits in glutamate transporters in this rat model may be glial specific. Riluzole, a neuroprotective agent used clinically to slow the progression of ALS, produced an enhancement of spinal cord amino acid carrier 1) in spinal cord of end-stage G93A rats, indicating that deficits in glutamate transporters in this rat model may be glial specific.

Key words: Cu2+/Zn2+ superoxide dismutase; ALS; GLT-1; GLAST; glutamate; riluzole

Introduction

Amyotrophic lateral sclerosis (ALS) is a late-onset neurodegenerative disease involving progressive motor neuron degeneration, paralysis, and death (Brown, 2001; Cleveland and Rothstein, 2001; Cluskey and Ramsden, 2001). A glutamatergic hypothesis has been proposed as one of the mechanisms contributing to the degeneration of motor neurons in ALS (for review, see Plaitakis et al., 1996). Several independent lines of evidence have provided support for an impaired capacity for the clearance of extracellular glutamate as a contributing factor in ALS. Elevated extracellular glutamate levels have been documented in plasma and CSF from ALS patients (Rothstein et al., 1990, 1991) and in cortical microdialysates from a transgenic mouse model of ALS (Alexander et al., 2000). Impaired glutamate uptake capacity has been described using spinal cord and motor cortex synaptosomes from human postmortem ALS tissue (Rothstein et al., 1992). Recently, it was shown that 41% of ALS patients have elevated CSF glutamate levels, which correlated to a spinal onset of disease and severity of symptoms (Spreux-Varoquaux et al., 2002). At the molecular level, a selective loss of the predominant CNS glutamate transporter EAAT2 (GLT-1) in spinal cord as well as motor cortex from ALS patients (Rothstein et al., 1995) suggests a potential mechanism for the elevated extracellular levels of glutamate and impaired capacity for uptake.

Transgenic mice harboring a human Cu2+/Zn2+ superoxide dismutase 1 (SOD1) transgene containing the G93A mutation (Gurney et al., 1994) exhibit impaired capacity for spinal cord high-affinity glutamate uptake (Canton et al., 1998). No data however were presented regarding glutamate uptake in tissue other than spinal cord in the G93A mouse. With respect to expression of the glutamate transporter GLT-1, conflicting results have been reported in G93A mice. Consistent with the reported decrease in spinal cord glutamate uptake, a decrease in GLT-1 immunoreactivity in spinal cord has been reported with no change in the levels of the other astroglial transporter GLAST (Bendotti et al., 2001). However, another group recently reported no change in the net amount of GLT-1 protein in the spinal cord, cortex, and brainstem of G93A mice but rather observed a qualitative molecular weight change in the GLT-1 monomer as well as increases in dimeric GLT-1 (Deitch et al., 2002).

Recently, transgenic rats expressing human SOD1 G93A have been generated (Howland et al., 2002) that develop an ALS-like phenotype, including motor neuron degeneration in the spinal cord. A pronounced loss of GLT-1 occurs in the ventral horn of G93A rats at end stage (Howland et al., 2002). In the current study, we extend these observations by evaluating functional glutamate uptake capacity in specific regions of the nervous system in transgenic G93A rats. Our findings reveal a correlation between altered expression of glial glutamate transporters to loss in...
maximal velocity ($V_{\text{max}}$) of glutamate uptake. Finally, we report an attenuated effect of the ability of riluzole to enhance spinal cord synaptosomal glutamate uptake as a function of disease progression in the G93A rat and implicate loss of GLT-1 as the cause.

Materials and Methods

Materials. Transgenic G93A rats (Howland et al., 2002) were maintained according to Institutional Animal Care and Use Committee approved protocols, and age-matched control Sprague Dawley rats were either bred (littermate controls) or purchased from Taconic (Germantown, NY). $t^{-}[\text{H}]{\text{H}}$Glutamate (specific activity, 40–60 Ci/mmol) was obtained from Amersham Biosciences (Buckinghamshire, UK); $t^{-}\text{trans}-\text{pyrrolidine-2,4-dicarboxylate (trans-PDC), dihydrokainate (DHK), and riluzole were from}$ Tocris (Ballwin, MO), and $t$-glutamate was from Sigma (St. Louis, MO). Primary antibodies for immunoblots were obtained from the following sources: GLT-1, Chemicon (Temecula CA); GLAST, Abcam (Cambridge, UK); EAAC1 (excitatory amino acid carrier 1), Zymed (South San Francisco, CA) and J. Rothstein (Johns Hopkins School of Medicine, Baltimore, MD); synaptophysin, Santa Cruz Biotechnology (Santa Cruz, CA); actin, Sigma; and glial fibrillary acidic protein (GFAP), Research Diagnostics (Flanders NJ). Secondary antibodies, linked to horseradish peroxidase (HRP), were obtained from Bio-Rad (Hercules, CA) (anti-mouse, anti-rabbit, and anti-goat) or Research Diagnostics (anti-guinea pig).

Preparation of synaptosomes. Specific regions of the nervous system, including spinal cord, cortex, hippocampus, striatum, cerebellum, and brainstem, were dissected, collected in ice-cold isolation medium (310 mM sucrose and 10 mM HEPES, pH 7.4), and homogenized with a Teflon–glass homogenizer, followed by centrifugation at 1000 × g for 5 min. The resulting supernatant was collected and centrifuged at 20,000 × g for 20 min to obtain the crude synaptosomal P2 pellet which was used at a protein concentration of 0.75 mg/ml in HEPES-buffered saline (HBS) (in mM: 10 HEPES, 5 Tris base, 140 NaCl, 2.5 KCl, 1.2 CaCl$_2$, 1.2 MgCl$_2$, 1.2 K$_2$HPO$_4$, and 10 glucose, pH 7.4). Protein concentration was determined by a modified Bradford method using the commercially available Bio-Rad protein assay kit. Synaptosomal pellets were kept on ice under isolation medium and were resuspended in HBS at room temperature 15–30 min before the assay of $t^{-}[\text{H}]{\text{H}}$glutamate uptake.

Glutamate uptake assays. Uptake studies in synaptosomes were performed with synaptosomal P2 fractions isolated from cervical spinal cord or the specified brain regions. $t^{-}[\text{H}]{\text{H}}$Glutamate uptake was assayed in a final volume of 250 µl of HBS containing 75 µg of synaptosomal protein, 1 µM $t$-glutamate, and 0.25 µCi/assay $t^{-}[\text{H}]{\text{H}}$glutamate in the absence and presence of inhibitors for the determination of IC$_{50}$ values. Kinetic experiments were undertaken in the presence of 1–30 µM $t$-glutamate in the presence of 0.25 µCi/assay $t^{-}[\text{H}]{\text{H}}$glutamate as tracer. The effect of riluzole was evaluated by preincubating synaptosomes with the indicated concentrations for 10 min, followed by measurement of $t^{-}[\text{H}]{\text{H}}$glutamate uptake, as described above for the inhibitors, in the continued presence of riluzole. Reactions were incubated for 4 min at room temperature and then terminated by filtration using a Packard Filtermate 90-well harvester, followed by rapid washing with ice-cold Na$^{-}$-free HBS (prepared by equimolar replacement with choline). Radioactivity retained on the filters was determined by scintillation counting. In all uptake experiments, the radioactivity retained after incubation in Na$^{-}$-free HBS was used to correct all data to represent Na$^{-}$-dependent uptake.

Histochemical analysis. Animals were anesthetized using approved animal welfare protocols and perfused by cardiac puncture with 4% paraformaldehyde–PBS. Brain and spinal cord were removed, followed by regional dissection. Tissue blocks were embedded in paraffin for sectioning (7 µm). Hematoxylin and eosin stains of brain and spinal cord were performed on paraffin sections. Immunostaining was performed with antibody to glial fibrillary acidic protein, GFAP (1:50; Dako, Copenhagen, Denmark).

Immunoblot analysis of glutamate transporters. The expression of GLT-1, GLAST, and EAAC1 in whole spinal cord and brainstem homogenates was examined by immunoblot. Whole cervical spinal cord or brainstem (~0.2 gm) was homogenized in 2 ml of 50 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 1% Nonidet P-40, and 1% SDS, pH 7.4, with protease inhibitors (Complete; Roche, Indianapolis, IN) and centrifuged at 14,000 × g. Five to 25 µg of total extract protein was electrophoresed on 7.5% SDS–polyacrylamide gels. Immunoblots were probed with anti-GLT-1 (1:5000), anti-GLAST (1:2000), anti-EAAC1 (1:500), anti-GFAP (1:5000), anti-actin (C4; 1:5000), or anti-synaptophysin (1:5000) antibodies. Secondary antibodies conjugated to HRP used at 1:2000 were followed by signal detection using ECL (Amersham Biosciences, Piscataway NJ).

Data analysis. All data for uptake assays were corrected to represent Na$^{-}$-dependent uptake by subtraction of the uptake observed in the absence of extracellular Na$^{-}$. Kinetic data were determined by nonlinear regression analysis of the saturation curves using the following Michaelis-Menten equation: velocity = $V_{\text{max}}[S] / (K_m + [S]),$ where $[S]$ is substrate concentration, using Origin 6.0 software (Microcal Software, Northampton, MA). In the pharmacological experiments, control uptake was calculated as the total Na$^{-}$-dependent uptake measured over 4 min, and drug effects were expressed as a percentage of the control response. Log concentration–response curves were constructed for the determination of IC$_{50}$ values using the following four-parameter logistic function: $y = (\text{Top} - \text{Bottom}) / (1 + (x/\text{IC}_{50}^\text{p}))) + \text{Bottom},$ where $p$ represents the Hill coefficient.

Quantitation of immunoblots was done using Scion Image software. Statistical analyses were performed using between-groups ANOVA, followed by Dunnett’s t test.

Results

Spinal cord synaptosomal uptake of glutamate

High-affinity Na$^{-}$-dependent glutamate uptake was examined in spinal cord synaptosomes prepared from presymptomatic (8–10 weeks), disease onset (13–15 weeks), and end-stage (15–17 weeks) G93A rats and compared with the activity measured in age-matched control (nontransgenic) animals. Onset of the disease was typified by the appearance of hindlimb abnormal gait, followed by a rapid progression (<2 weeks) to complete hindlimb paralysis, with end-stage animals characterized with a loss of righting reflex concomitant with paralysis extending to at least one forepaw (Table 1). No difference in the $V_{\text{max}}$ of glutamate transport in spinal cord synaptosomes was observed with presymptomatic animals compared with controls; however, a reduction in the $V_{\text{max}}$ was observed coincident with disease onset and was more dramatic at end stage (Fig. 1). $V_{\text{max}}$ values were 161 ± 16 and 92 ± 17 pmol · min$^{-1}$ · mg$^{-1}$ for control and disease end-stage G93A rats, respectively, representing a 43% decrease in total transport capacity. At disease onset, the reduction in $V_{\text{max}}$ in the G93A animals was 27% relative to controls, and no changes in the affinity for glutamate were observed over developmental time between transgenic and control rats ($K_m$ values were in the range of 3–8 µM).

With each preparation of synaptosomes, we also examined the sensitivity of the transport process to the nonselective glutamate uptake blocker trans-PDC and the selective GLT-1/EAAT2 inhibitor DHK. Inhibitor sensitivity, in combination with Na$^{-}$ dependency of uptake, was evaluated as an index of the integrity of the synaptosomal preparations, and the analysis was also performed

<table>
<thead>
<tr>
<th>Group classification</th>
<th>Clinical signs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presymptomatic</td>
<td>Full mobility and no observable difference in behavior from age-matched controls</td>
</tr>
<tr>
<td>Onset</td>
<td>Observation of abnormal gait or hindlimb weakness</td>
</tr>
<tr>
<td>End stage</td>
<td>Overall muscle wasting and complete hindlimb paralysis indexed as an inability to right themselves in a 30 sec time window; typically accompanied by paralysis of at least one front limb</td>
</tr>
</tbody>
</table>

Table 1. Clinical classification of G93A SOD1 transgene-induced disease progression
onset or end-stage G93A rats compared with either their corresponding age-matched controls (Fig. 2b,c) or the results obtained for presymptomatic animals. A summary of the pharmacological comparison for spinal cord synaptosomes is provided in Table 2.

Loss of glutamate uptake enhancement by riluzole in end-stage spinal cord from G93A rats

Riluzole, a neuroprotective agent used clinically to slow the progression of ALS, has been reported to increase the glutamate transport capacity in spinal cord synaptosomes (Azbill et al., 2000). Coincubation with riluzole (10–300 μM) produced a 25–30% increase in the glutamate uptake measured with spinal cord synaptosomes prepared from G93A rats at disease onset, and the enhancing effect was similar in the corresponding control animals (Fig. 3a). In contrast, the stimulatory effect of riluzole was blunted with spinal cord synaptosomes prepared from end-stage G93A rats in which a significantly reduced (<10%) increase in the glutamate transport activity was observed compared with a 30% increase observed with the age-matched controls (Fig. 3b).

Disease changes and synaptosomal glutamate uptake in various brain regions

Spinal cord from end-stage G93A transgenic rats shows a complete loss of ventral large motor neuron cell bodies (Fig. 4A) as well as dramatic increases in gliosis (Fig. 4A,B) but only few vacuoles. Vacuoles appear in higher abundance in earlier stages of disease in these rats (Howland et al., 2002) but disappear by end stage, possibly reflecting the severity of damage. Brainstem of G93A rats show a profound vacuolization (Fig. 4C), as well as an increased gliosis at end-stage disease; however, neuronal cell loss is not as profound as that observed in the end-stage diseased spinal cord (Fig. 4) (Howland et al., 2002). Other brain regions surveyed (Fig. 4D,E, neocortex and hippocampus, respectively) show no degenerative signs of pathology.

High-affinity Na⁺−dependent glutamate uptake was examined in synaptosomes prepared from cortex, hippocampus, striatum, cerebellum, and brainstem using end-stage G93A rats and compared with the activity measured in the same tissues from age-matched control animals. In contrast to what we observed in G93A rat spinal cord, there was no difference in either the $V_{\text{max}}$ or $K_m$ values for glutamate uptake in cortical, hippocampal, striatal (Fig. 5), cerebellar, or brainstem (Fig. 6) synaptosomes between end-stage disease G93A and age-matched control animals. Similarly, we observed no difference in the pharmacological sensitivity to either trans-PDC or DHK using synaptosomes prepared from these same brain regions when comparing G93A rats with control animals (Table 3). Both trans-PDC and DHK were effective blockers of glutamate uptake in all regions examined, with the exception of DHK in cerebellar synaptosomes in which 50% inhibition of uptake was not achieved, even at 1 mM.

Expression analysis of GLT-1, GLAST, and EAAC1 in spinal cord and brainstem of G93A rats

Whole cervical spinal cord from end-stage G93A rats and nontransgenic age-matched controls (16–20 weeks) were analyzed for levels of glial glutamate transporters GLT-1 and GLAST, as well as the neuronal transporter EAAC1, by immunoblot analysis (Fig. 7A). In addition, immunoblots were probed with antibodies to GFAP to index the extent of gliosis, synaptophysin to index the degree of neuronal cell loss, and actin to control for protein loading. A significant decrease of GLT-1 of 45% was observed in end-stage cervical spinal cord of the G93A rats compared with controls (Fig. 7A). No consistent changes in gel migration of the
72 kDa GLT-1 monomeric species were observed between control and end-stage disease tissue, in contrast to that reported by Deitch et al. (2002) for the G93A transgenic mice. Qualitative changes in GLAST immunoreactivity, however, were consistently observed in end-stage spinal cord of the G93A rats, but total immunoreactivity was not significantly different from controls. GLAST in control spinal cord migrated as a doublet, with the major band migrating at 65 kDa (Fig. 7 A). However, a more complex pattern was observed in end-stage G93A rat spinal cord. A new band of intermediate molecular weight appeared in end-stage G93A spinal cords. The intensity of this species was more pronounced in animals that had most severe clinical symptoms (Fig. 7A). No significant changes in EAAC1 immunoreactivity in end-stage disease G93A spinal cord versus controls was evident using two different antisera (Zymed) (Rothstein et al., 1995).

End-stage G93A rats exhibit extensive gliosis as well as neuron cell loss in the spinal cord (Fig. 4 A, B) (Howland et al., 2002). We probed spinal cord immunoblots with anti-GFAP as well as anti-synaptophysin antibodies to attempt to correlate the degree of gliosis and cell loss in G93A spinal cords. The extent of these changes was most marked in most severely affected animals.

In contrast to GLT-1 changes in spinal cord, we observed no consistent changes in GLT-1 immunoreactivity in brainstem of end-stage G93A rats (Fig. 7B). A slightly decreased mobility for the 65 kDa form of GLAST was evident in brainstem but was not as dramatic as that seen in spinal cord from end-stage diseased rats. No significant changes in EAAC1 immunoreactivity were noted in the brainstem of the G93A rats. As expected, GFAP immunoreactivity was significantly elevated in brainstem (two-fold) of the G93A rats; however, no significant changes in synaptophysin immunoreactivity were noted, consistent with a lower degree of neuron cell loss in brainstem compared with spinal cord. Cortex of the G93A end-stage rats as well as controls were also analyzed in a similar manner as for spinal cord and brainstem.
stem; however, no changes in any of the transporters was noted in this brain region (data not shown).

Glutamate transporter levels were also assessed in the G93A rat spinal cord at different stages of disease (nontransgenic, presymptomatic, onset, and end stage) (Fig. 8). Reduced levels of GLT-1 were evident as well as GLAST, showing altered gel migration in all G93A rats at end stage. GLT-1 changes, however, were not typically evident in G93A rats at disease onset or in presymptomatic rats when analyzing whole spinal cord tissue. However, we showed previously that, when rat spinal cord is microdissected into ventral and dorsal horns, decreased levels of GLT-1 are evident as early as 100 d old (late presymptomatic) (Howland et al., 2002). Sampling whole spinal cord most likely dilutes the magnitude of the measurable decrease in GLT-1 immunoreactivity, which appears to be ventral horn specific, and results in a shift to later time points when quantitative differences can be measured. A similar phenomena was reported by Bendotti et al. (2001) in transgenic SOD1 mice. GFAP immunoreactivity increased with disease progression in G93A spinal cord, reaching its peak in end-stage rats. Decreased synaptophysin was not evident until end-stage disease, with the exception of one animal at disease onset (Fig. 8).

**Discussion**

We describe a kinetic and pharmacological characterization of synaptosomal glutamate transport capacity in multiple regions of the nervous system using a recently developed transgenic rat model of ALS overexpressing the human G93A mutant Cu,Zn-superoxide dismutase 1 gene (Howland et al., 2002). Our results indicate a selective deficit in glutamate uptake activity in synaptosomes prepared from spinal cord, with no changes detected in various brain regions, including cortex, hippocampus, striatum, cerebellum, and brainstem. The reduced glutamate transport capacity measured in spinal cord synaptosomes was restricted to animals exhibiting signs of disease onset (13–15 weeks) and at end stage of the disease (15–17 weeks). At end stage, the loss of glutamate transport capacity was most dramatic, with a 43% reduction in the $V_{\text{max}}$ detected compared with a 27% loss observed with animals at disease onset. Although a reduced maximal capacity for glutamate uptake was demonstrated in both disease onset and end-stage G93A rats, there was no change in the affinity ($K_m$) for the substrate at any developmental time point of the disease, a result consistent with no change in the pharmacological specificity of glutamate uptake as disease progresses.

We examined glutamate uptake in tissue known to contain ALS-like lesions in the G93A transgenic rats (spinal cord and brainstem) as well as regions devoid of pathology (cortex, hippocampus, striatum, and cerebellum). Functional glutamate transport is only deficient in spinal cord of the G93A rats, is evident as early as disease onset, and becomes more severe by end stage. Our results in end-stage diseased spinal cord are similar to those described previously for transgenic mice harboring the same G93A mutant form of SOD1 (Canton et al., 1998). That study, however, did not report on the effect of the G93A mutation on glutamate transport in the brainstem as well as other brain regions. Here, we showed that no measurable change in glutamate transport occurs in the brainstem, despite the presence of pathological changes. Although vacuolization is quite extensive in end-stage G93A brainstem, the extent of neuron cell loss is not as severe as that observed in the spinal cord. Sparing of glutamate transport function, despite some pathological changes, may be related to lesser degree of neuron cell loss in the brainstem of the G93A rat.

Studies with synaptosomal preparations prepared from post-mortem human ALS tissue have described a marked reduction in the maximal velocity of glutamate transport in spinal cord (−59%), motor cortex (−70%), and somatosensory cortex (−39%) synaptosomes, with no accompanying change in $K_m$ (Rothstein et al., 1992). The data reported here on the G93A rat are consistent with a deficit in glutamate uptake in spinal cord of ALS patients and lack of a deficit in brain regions known to be spared of ALS-like lesions. However, the transgenic rat differs in that glutamate uptake capacity is spared in brainstem, a region that shows some pathological changes in the G93A rat as well as in ALS.

A molecular mechanism for the deficits in glutamate clearance...
Figure 4. Histochemical analysis of pathology in end-stage G93A transgenic rat spinal cord and brain regions. Cervical spinal cord (A) or brain areas including brainstem (C), neocortex (D), and hippocampus (E) were stained with hematoxylin and eosin to show extent of neuronal loss, degenerative structures (vacuoles), as well as gliosis in end-stage G93A rats compared with age-matched control rats (Con). Arrows in A and C denote the presence of large motor neuron cell bodies, rarely found in end-stage diseased spinal cord. Representative spinal cord sections from control and end-stage G93A rats are also shown stained with anti-GFAP antibody (B). Arrows in B highlight a hypertrophic astrocyte, frequently found in end-stage diseased spinal cord.

Figure 5. Saturation isotherms for the high-affinity Na\(^+/\)H\(^+-\)dependent transport of glutamate in cortical (a), hippocampal (b), and striatal (c) synaptosomes prepared from end-stage G93A transgenic rats and age-matched controls. Glutamate uptake into P2 synaptosomal fractions was measured as described in Materials and Methods for the estimation of the kinetic parameters \(K_m\) and \(V_{max}\). Initial rates of Na\(^+/\)H\(^+-\)dependent glutamate uptake were expressed as picomoles per minute per milligram of synaptosomal protein after subtraction of the uptake observed in the absence of extracellular Na\(^+\) (equimolar replacement of NaCl with choline chloride). Kinetic constants \(K_m\) and \(V_{max}\) were estimated from the saturation isotherm using the Michaelis-Menten equation and are presented in Table 3. Data represent mean \(\pm\) SEM values from three independent experiments.
capacity was initially suggested in the human study with the demonstration that expression levels of the glial-specific glutamate transporter EAAT2 (GLT-1) were dramatically reduced in both spinal cord and motor cortex (Rothstein et al., 1995). Because GLT-1 is considered to account for a large proportion of the glutamate transport capacity in the nervous system, its loss is consistent with both a reduction in glutamate uptake capacity and elevated extracellular glutamate, as demonstrated in both CSF and plasma in ALS patients (Rothstein et al., 1992; Spreux-Varoquaux et al., 2002). Consistent with the loss of GLT-1 protein described in human ALS patients (Rothstein et al., 1995), a 50% loss of spinal cord homogenate GLT-1 protein has also been detected in transgenic mice expressing another mutant form of SOD1 incorporating a G85R mutation, at end stage (Brujin et al., 1997).

Immunohistochemical methods were also used to demonstrate reductions of GLT-1 in G93A transgenic mouse spinal cords at 14–18 weeks in age, a time when motor impairments is evident (Bendotti et al., 2001). However, the loss of total GLT-1 protein in the G93A transgenic mouse has been questioned recently given the observations of Deitch et al. (2002), who were unable to detect a net loss of GLT-1 protein but rather reported a mobility shift of GLT-1 monomer to a higher molecular weight, thought to result from an unidentified posttranslational modification. This latter observation is not inconsistent with the loss of functional uptake in these animals because aberrant processing of the protein could result in altered function. We demonstrate a loss of GLT-1 immunoreactivity in end-stage diseased G93A rats and spinal cords. We did not consistently observe gel migration dif-

Table 3. Kinetic parameters and inhibitor IC50 values for glutamate uptake in synaptosomes prepared from various brain regions of transgenic G93A rats and age-matched controls

<table>
<thead>
<tr>
<th>Brain Region</th>
<th>Vmax (pmol/min/mg protein)</th>
<th>Km (μM)</th>
<th>PDC (μM)</th>
<th>DHK (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cortex</td>
<td>669 ± 16</td>
<td>8 ± 1</td>
<td>2.1 ± 0.3</td>
<td>38.2 ± 0.5</td>
</tr>
<tr>
<td>G93A</td>
<td>603 ± 74</td>
<td>7 ± 0</td>
<td>2.0 ± 0.1</td>
<td>31.9 ± 7.2</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>503 ± 39</td>
<td>5 ± 0</td>
<td>1.8 ± 0.1</td>
<td>35.7 ± 10.9</td>
</tr>
<tr>
<td>G93A</td>
<td>523 ± 96</td>
<td>6 ± 0</td>
<td>1.7 ± 0.2</td>
<td>35.1 ± 6.2</td>
</tr>
<tr>
<td>Striatum</td>
<td>422 ± 60</td>
<td>5 ± 0</td>
<td>1.7 ± 0.1</td>
<td>32.0 ± 6.1</td>
</tr>
<tr>
<td>G93A</td>
<td>378 ± 72</td>
<td>6 ± 0</td>
<td>1.8 ± 0.4</td>
<td>31.5 ± 5.0</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>74 ± 8</td>
<td>6 ± 0</td>
<td>3.6 ± 0.3</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>G93A</td>
<td>65 ± 5</td>
<td>5 ± 0</td>
<td>3.3 ± 0.3</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Brainstem</td>
<td>127 ± 20</td>
<td>6 ± 0</td>
<td>2.0 ± 0.2</td>
<td>87.6 ± 22.4</td>
</tr>
<tr>
<td>G93A</td>
<td>123 ± 29</td>
<td>6 ± 1</td>
<td>2.0 ± 0.1</td>
<td>79.3 ± 19.5</td>
</tr>
</tbody>
</table>

Glutamate uptake in synaptosome fractions prepared from the indicated brain regions of G93A and age-matched control (CON) rats was evaluated at end stage of disease progression. Kinetic parameters and Km values are mean ± SEM values from three independent experiments.
glutamate transport capacity observed in the spinal cord of G93A expression of GLAST or EAAC1 immunoreactivity. The loss of cord homogenates by immunoblot analysis and the relatively low is consistent with the reported high expression of GLT-1 in spinal gests that the GLT-1 subtype of glutamate transporter predomi-

nantly mediates the measured transport activity. This conclusion with no changes in inhibitor IC50 observed as the disease pro-
gress. Sensitivity to DHK in the spinal cord preparation sug-

erved an enhancement of glutamate uptake activity in spinal cord synaptosomes treated with riluzole in vitro, although we were unable to demonstrate an effect with 0.1 μM riluzole, in contrast to the study of Azbill and coworkers, with concentra-
tions in the range of 10–300 μM being effective in the present study at producing a 25–30% increase in the uptake of 1 μM glutamate. More interestingly, we observed a consistent reduc-
tion in the enhancing effect of riluzole in spinal cord synap-
tosomes prepared from end-stage G93A rats, although similar studies with tissue derived from disease onset animals revealed an equivalent enhancement by riluzole in transgenic compared with control animals. Because the neuroprotective activity associated with riluzole might be attributed at least in part to this facilitated extracellular glutamate clearance, the attenuation of the enhanc-
ing activity demonstrated at end-stage disease in the current study raises the intriguing possibility that the efficacy of this drug might be reduced with disease progression in ALS patients.

In summary, we demonstrated marked deficits in glutamate uptake in spinal cord, but not brainstem and other brain areas not affected by disease, in the G93A transgenic rat. Reductions in spinal cord glutamate transport capacity are accompanied by al-
tered expression of astroglial glutamate transporters GLT-1 and GLAST. Significant deficits in glutamate uptake mediated by gial cells is likely to be the cause for loss of efficacy of riluzole to potentiate glutamate uptake in end-stage G93A spinal cord com-
pared with rats at earlier stages of disease. On the basis of these data, it is possible that the effectiveness of riluzole in ALS patients in latter stages of disease may be dampened compared with pa-
tients at earlier stages of disease on this drug therapy.

References
Benavides J, Camelin JC, Mitraní N, Flamand F, Uzan A, Legrand JJ, Gueremy...


